No Data
No Data
H.C. Wainwright Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20
Express News | Actuate Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $20
Actuate Therapeutics | 10-K: FY2024 Annual Report
Express News | Actuate Completes Enrollment In Phase 2 Trial Of Elraglusib Plus FOLFIRINOX And Losartan
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination With FOLFIRINOX and Losartan in Patients With Previously Untreated Metastatic Pancreatic Cancer
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?